From public research to business innovation!

TMZ : Innovative stratification and therapy for lung cancer management

Domain Health and wellbeing

Technology Metaomic

Challenges

Need to find new patients stratification and target

  • Every 4 minutes, 10 people die from lung cancer in the world
  • Poor outlook for advanced and metastatic patients (5yr survival rate <10% for advanced stages)
  • Chemotherapy remains the backbone with many side effects and poor success
  • Targeted therapy (EGFR, BRAF) only targets few patients and resistance comes rapidly
  • Immunotherapy works well only on a small number of patients, and it is very expensive

 

 Research team identified oxidative lung tumors,  with a high mitochondrial respiration metabolism,  in 50% of pulmonary adenocarcinomas.

Innovative solution

Bioenergetic precision medecine

  • New stratification : oxidative (OX+) lung  tumors , based on HADHA immunohistology scoring
  • New target : HADHA enzyme, overexpressed in OX+ tumors
  • New drug HADHA inhibitor, reducing tumor proliferation

Competitive advantages

Unique targeted therapy based on energy metabolism

  • Biomarkers for new patients stratification and aid for therapeutic orientation
  • OX+ drug usable alone or in combination with current therapies
  • Alternative solution for chemotherapy resistance
  • Companion test for OX+ patients

Inventors

Rodrigue ROSSIGNOL, PhD

Cellular bioenergetics in human physiology and pathology

University of Bordeaux - Rare Diseases, Genetics and Metabolism (MRGM, UMR, 1211)

IP

PCT/EP2018/086278 à Claims multifunctional FAO-OXPHOS complex inhibitor for use in the treatment of high mitochondrial respiration (OX+) cancer.

Contact

Jean-Luc CHAGNAUD

%6a%6c%2e%63%68%61%67%6e%61%75%64%40%61%73%74%2d%69%6e%6e%6f%76%61%74%69%6f%6e%73%2e%63%6f%6d

 

We also recommend...